



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH




13 March 2015

Science, Medicines, Health: Patients at the heart of future innovation

Conference programme

18 March 2015

East Wintergarden, 43 Bank Street, London E14 5NX, United Kingdom



Welcome to all participants

When the European Medicines Agency was created 20 years ago, the European Union was a smaller place and European healthcare and its regulatory environment looked vastly different from what we see today. The changing healthcare needs of our patients, advancements in science and medicine, the enlargement of the European Union, and legislative changes have shaped the Agency's growth over the first two decades. From our humble beginnings with just 16 staff members and two committees in 1995, we've now expanded to an Agency with about 900 staff and seven scientific committees supporting 28 Member States to ensure that medicines for people and animals in Europe are safe, effective and of high quality.

Patients have always been at the heart of our work aimed at allowing all European patients to benefit from advancements in science, medicines and health. We remember with some nostalgia the first product to be centrally authorised on 20 October 1995. Today, almost all new and innovative medicines are authorised centrally, resulting in significantly improved access for all European patients.

We have come a long way in many areas. Latest milestones include the establishment of the Pharmacovigilance and Risk Assessment Committee set up in 2012 to better monitor and act upon safety issues around medicines or the landmark policy on the publication of clinical study reports that will enter into force in January 2015.

However, there is no room for complacency as we are confronted with numerous challenges that need to be tackled also on the regulatory front, such as the scourge of chronic diseases including cancers and heart diseases, the global threat of antibiotic resistance and public health emergencies such as Ebola, to name but a few. In addition, there are still diseases for which no treatment is available.

We expect that shifts in healthcare systems and rapid scientific progress will change the way medicines are developed and brought to patients in the future, and regulators will have to respond accordingly. We need to seize new opportunities and address challenges together with all our stakeholders so that we continue to deliver on our mission to foster scientific excellence in the evaluation and supervision of medicines, for the benefit of public and animal health. We therefore see the anniversary conference "**Science, Medicines, Health: Patients at the heart of future innovation**" as an ideal forum to discuss with many of our important stakeholders, how to best support innovation in order to increase public health.

I warmly invite you to join us and our panel of esteemed speakers for what promises to be an exciting and dynamic conference.

Andreas Pott

Deputy Executive Director

Programme details – Wednesday 18 March 2015

10.00 Registration

Please pick up your badge and enjoy refreshments in the meeting room

11.00 Welcome and Opening

Guido Rasi, Principal Adviser in Charge of Strategy, European Medicines Agency

Ladislav Miko, Acting Director General for Health and Food Safety (DG SANTE), European Commission

11.15 Congratulatory Speech

Margaret Hamburg, Commissioner, US Food and Drug Administration

11.30 Keynote Address: What I expect from EMA for the next 5 years

Elias Zerhouni, President, Global R&D, Sanofi

The Innovator's Perspective

Sir Mark Walport, Chief Scientific Adviser to Her Majesty's Government

The Public Health Perspective

12.30 Lunch break

A finger buffet-style lunch will be served at East Wintergarden

13.30 Panel Discussion (Moderator: **Malcolm Rowland**, Professor Emeritus, School of Pharmacy, University of Manchester)

Yann Le Cam, Chief Executive Officer, EURORDIS, France

The Patients' Perspective

Carole Longson, Director, Centre for Health Technology Evaluation, NICE, UK

The HTAs/Payers' Perspective

Andrea Ponti, Partner, GHO Capital Partners LLP, UK

The Investor's Perspective

Adam Cohen, Professor of Clinical Pharmacology, University of Leiden, NL

The Academic's Perspective

Tomas Salmonson, Chair, EMA's Committee for Human Medicinal Products

The Regulator's Perspective

Hans-Georg Eichler, Senior Medical Officer, European Medicines Agency

The Regulator's Perspective

15.45 Thank you and Closing

Sir Kent Woods, Chair, EMA's Management Board

Conference secretariat

European Medicines Agency
30 Churchill Place, Canary Wharf
London E14 5EU, United Kingdom
Telephone +44 (0) 77 65 858 611
E-mail Anniversary@ema.europa.eu
Website www.ema.europa.eu

Conference venue

East Wintergarden
43 Bank Street, Canary Wharf
London E14 5NX, United Kingdom

Website <http://canarywharf.com/east-wintergarden/>